Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

/PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK) ("Mallinckrodt" or the "Company"), a global specialty pharmaceutical company, today announced that Dr....

Related Keywords

United States ,Adare ,Limerick ,Ireland ,United Kingdom ,Dublin ,Nottingham ,American ,Steven Romano ,Aaron Palash ,Daniel Speciale ,Michael Freitag ,Joele Frank ,Peter Richardson ,Siggi Olafsson ,Prnewswire Mallinckrodt ,Derek Belz ,Wilkinson Brimmer Katcher ,University Of Nottingham Medical School ,Head Of Research ,Mallinckrodt Pharmaceuticals ,Royal College Of Physicians ,Antares Pharmaceuticals ,Novartis ,Global Head Of Development Alliances ,Mannkind Corporation ,Novartis Pharmaceuticals ,American Company Guide The ,Company Specialty Brands ,Compensation Committee Of The Board ,Stanford University Graduate School Of Busines ,Adare Pharmaceuticals ,University Of Nottingham ,Novartis Company ,Exchange Commission ,Company Executive Committee ,Regulatory Affairs At Alcon ,Executive Vice President ,Chief Scientific Officer ,Executive Committee ,Chief Medical Officer ,Chief Executive ,Company Guide ,Human Resources ,Compensation Committee ,Antares Pharmaceutical ,Vice President ,Global Clinical ,Regulatory Affairs ,Corporate Vice President ,Senior Vice President ,Global Head ,Nottingham Medical ,Stanford University Graduate School ,Royal College ,Specialty Brands ,Specialty Generics ,Investor Relations ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Corporate Controller ,Chief Investor Relations ,Wilkinson Brimmer ,Mallinckrodt Plc ,